Two Sigma Investments LP lessened its stake in Sientra Inc (NASDAQ:SIEN) by 18.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,666 shares of the medical instruments supplier’s stock after selling 21,164 shares during the period. Two Sigma Investments LP owned 0.19% of Sientra worth $184,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Citigroup Inc. boosted its position in Sientra by 6,407.7% in the 4th quarter. Citigroup Inc. now owns 62,995 shares of the medical instruments supplier’s stock valued at $563,000 after buying an additional 62,027 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Sientra by 55.7% during the fourth quarter. Bank of New York Mellon Corp now owns 243,492 shares of the medical instruments supplier’s stock valued at $2,176,000 after acquiring an additional 87,129 shares during the period. State Street Corp boosted its holdings in Sientra by 32.1% in the fourth quarter. State Street Corp now owns 727,107 shares of the medical instruments supplier’s stock valued at $6,500,000 after acquiring an additional 176,835 shares during the last quarter. Marshall Wace North America L.P. acquired a new stake in Sientra in the fourth quarter worth about $1,250,000. Finally, Baird Financial Group Inc. increased its position in Sientra by 24.4% in the fourth quarter. Baird Financial Group Inc. now owns 160,816 shares of the medical instruments supplier’s stock worth $1,438,000 after purchasing an additional 31,546 shares during the period. 76.99% of the stock is currently owned by hedge funds and other institutional investors.
Shares of SIEN stock opened at $3.87 on Wednesday. The company has a quick ratio of 1.72, a current ratio of 2.24 and a debt-to-equity ratio of 1.02. Sientra Inc has a 12-month low of $1.00 and a 12-month high of $9.71. The firm has a fifty day moving average of $3.79 and a 200-day moving average of $4.65. The firm has a market capitalization of $192.63 million, a price-to-earnings ratio of -1.48 and a beta of 1.45.
Several brokerages have recently issued reports on SIEN. Stephens reduced their target price on shares of Sientra from $10.00 to $5.00 and set an “overweight” rating on the stock in a research note on Monday, March 23rd. SVB Leerink reduced their price objective on shares of Sientra from $6.50 to $5.30 and set an “outperform” rating on the stock in a research note on Tuesday, May 12th. Maxim Group upped their target price on shares of Sientra from $5.00 to $8.00 in a research report on Thursday, June 11th. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Craig Hallum dropped their price objective on Sientra from $14.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, March 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. Sientra presently has a consensus rating of “Buy” and an average price target of $6.13.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: Understanding Market Liquidity
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.